The abstract is read at the publisher; the summary is JClub's.
PonatiLink-2, a bitopic ABL1 inhibitor, maintains or surpasses ponatinib potency against resistance mutants and shows an enhanced therapeutic window in vitro and in vivo.
- Why it matters: Kinase inhibitors often trade potency for selectivity because binding relies on a single conserved site, and ABL1 therapies face resistance mutations and off-target effects.
- What they did: Using ABL1 and EGFR as model kinases, the study systematically varies ligand choice, linkage vector, and linker length to tune potency via inter-ligand cooperativity and linker entropy.
- The result: In mouse models of BCR::ABL1-driven cancer, PonatiLink-2 outperforms clinically relevant treatments as combination with dasatinib against wild-type disease and as a single agent against ponatinib-resistant disease.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.